scorecardresearch
Sunday, July 20, 2025
TopicSun Pharma

Topic: Sun Pharma

Gujarat to get Rs 150 cr leadership institute—Modi’s brainchild, backed by India’s top Industry leaders

Former finance secretary Hashmukh Adhia has been appointed the chairman of the executive committee of School of Ultimate Leadership (SOUL).

US drug regulator halts Sun Pharma trials on dermatological drug

Sun Pharma, India's largest drugmaker by revenue, acquired deuruxolitinib when it bought US-based Concert Pharmaceuticals for $576 million earlier this year.

US FDA asks India’s Sun Pharma to halt trials on experimental dermatological drug

Sun Pharma said FDA has also stated that patients with alopecia areata on 12 mg dose of the drug deuruxolitinib should discontinue its use, Sun Pharma said.

Sun Pharmaceutical flags revenue drop in its businesses due to ‘IT security incident’

The incident’s effect included breach of certain file systems and theft of some company and personal data, Sun Pharma said in a filing on Sunday.

Sun Pharma gets approval to test pancreatitis drug nafamostat for Covid treatment

Sun Pharma says nafamostat has shown promise in fighting against the virus in in-vitro studies conducted by 3 groups of scientists in Europe, Japan and South Korea.

China’s war on healthcare costs opens big window for India’s Sun Pharmaceuticals

China's ambitious multi-city bulk procurement program provides an opening for Indian manufacturers to compete.

Sun pharma falls after report of fresh whistle-blower complaint

Shares of India’s largest drugmaker fell as much as 13.2 percent.

On Camera

Can Syria’s tiny Druze minority survive West Asia’s new storms? There’s little hope

Indians see West Asia as one uninterrupted wash of Islam, but the reality is more complex. For the Druze, support from Israel—where they are a recognised minority—is now critical.

India-US set to ink mini trade deal soon, reach understanding on agricultural & dairy products

Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.

Not just AK-203, India & Russia to jointly manufacture AK-19 and PPK-20 for domestic use and export 

India-Russia JV is also racing to deliver 7,000 more AK-203 assault rifles by 15 Aug. These are currently being made with 50% indigenisation and this will surge to 100% by 31 December.

Strategic partner one day, tactical nightmare the next: India’s learning Trumplomacy the hard way

Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.